Match!
Christina A. Eichstaedt
Heidelberg University
58Publications
11H-index
778Citations
Publications 63
Newest
#1Christina A. Eichstaedt (Heidelberg University)H-Index: 11
#2Heimo Mairbäurl (University Hospital Heidelberg)H-Index: 29
Last.Ekkehard Gruenig (University Hospital Heidelberg)H-Index: 39
view all 11 authors...
Source
#1Zixuan Pan (University Hospital Heidelberg)H-Index: 2
#2Alberto M. MarraH-Index: 14
Last.Ekkehard Grünig (University Hospital Heidelberg)H-Index: 25
view all 16 authors...
The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary hypertension (PH). Thirty-eight SSc patients with mildly elevated mPAP at rest between 21 and 24 mmHg and/or > 30 mmHg during low-dose exercise were randomly assigned to treatment with either ambrisentan 5–10 mg/day or placebo. Right heart catheterization...
1 CitationsSource
#1Ekkehard Gruenig (University Hospital Heidelberg)H-Index: 39
#2Nicola Benjamin (University Hospital Heidelberg)H-Index: 8
Last.Andrew J. Peacock (Golden Jubilee National Hospital)H-Index: 45
view all 4 authors...
Multicentre trials on specialised exercise training and rehabilitation in patients with pulmonary hypertension are needed to provide further evidence on its haemodynamic effects and to show implementation in different healthcare systems is possible.http://bit.ly/2L4Mrgt
Source
#1P Xanthouli (University Hospital Heidelberg)H-Index: 1
#2N Milde (University Hospital Heidelberg)
Last.Ekkehard Grünig (University Hospital Heidelberg)H-Index: 25
view all 11 authors...
Source
#1Satenik Harutyunova (University Hospital Heidelberg)H-Index: 5
#2Nicola Benkamin (University Hospital Heidelberg)
Last.Ekkehard Gruenig (University Hospital Heidelberg)H-Index: 39
view all 7 authors...
Background: Prostacyclins (PCs) are used as targeted treatment for pulmonary arterial hypertension (PAH). Data regarding safety and long-term outcomes of s.c. and/or i.v. treprostinil (T) administered via s.c. Corno and the implantable LENUS Pro pump in patients with PAH are lacking. Methods: Thirty-seven PAH patients (20 females, 51±15 y.o., mean pulmonary arterial pressure 62.3±14.4 mmHg, cardiac index 2.4±0.7 L/min/m2, 6 WHO functional class II, 26 III, 5 IV) on triple targeted PAH medication...
Source
#1P Xanthouli (University Hospital Heidelberg)H-Index: 1
#2Nicklas Milde (University Hospital Heidelberg)
Last.Ekkehard Gruenig (University Hospital Heidelberg)H-Index: 39
view all 12 authors...
Background: Patients with systemic sclerosis (SSc) are at high risk of developing pulmonary hypertension (PH) which crucially affects patients’ symptoms, quality of life and prognosis. The aim of this study was to analyse the impact of the new hemodynamic definition of precapillary PH as proposed at the 2018 World Symposium on PH in SSc-patients. Methods: SSc-patients were screened for PH using clinical assessments as WHO-functional class, 6 minute walking distance (6MWD) and right heart cathete...
Source
Source
Purpose of reviewThe current review summarizes the latest evidence of the effects of exercise training for pulmonary hypertension patients demonstrated by six randomized controlled trails and 20 further studies. As the availability of exercise training is still limited it is important to raise aware
Source
Based on a small number of cases, interferon beta (IFN-β) has been added to the list of drugs that might induce pulmonary arterial hypertension (PAH) in the current European guidelines for the diag...
Source
#1Gabriele Grunig (NYU: New York University)H-Index: 20
#2Christina A. Eichstaedt (Heidelberg University)H-Index: 11
Last.Serhiy PylawkaH-Index: 2
view all 7 authors...
Source
1234567